OTTAWA--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) ("Avivagen"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the Second quarter of 2023.
"The Special Committee continues to examine all potential alternatives, including a strategic sale, in whole or in part, of the company", said Kym Anthony, Avivagen CEO. "To date, Avivagen has received numerous responses from firms wishing to engage in preliminary discussions regarding such alternatives".
Second Quarter April 30, 2023, Financial Results
The Company's unaudited Financial Statements for the second quarter ended April 30, 2023, and the accompanying Management's Discussion and Analysis have been filed on the System for Electronic Document Analysis and Retrieval and are available via its website (). The financial information for the second quarter ended April 30, 2023, should be read in conjunction with the Company's unaudited Financial Statements as well as its Management's Discussion and Analysis for the second quarter ended April 30, 2023
The Company reported net revenues of $77,683 and a comprehensive loss of $(1,244,829) for the three-month period ended April 30, 2023. This compares to revenues of $88,438 and a comprehensive loss of $(1,303,677) in the three-month period ended April 30, 2022.
For the six-month period ended April 30, 2023, the Company reported net revenues of $143,722 and a comprehensive loss of $(2,398,759). This compares to revenues of $359,595 and a comprehensive loss of $(2,856,529) in the six-month period ended April 30, 2022.
As of April 30, 2023, the Company reported total assets of $324,686 (current assets of $266,140), total liabilities of $8,633,272, and shareholders' deficit of $(8,308,586).
About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta Technology and OxC-beta Livestock
Avivagen's OxC-beta technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function, the technology provides a non-antibiotic means of promoting health and growth. OxC- beta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Mexico, Philippines, Taiwan China, New Zealand, Thailand, Australia and Malaysia. OxC-beta has been fed to over 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.
Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
加拿大渥太华--(BUSINESS WIRE)--Avivagen Inc.(TSXV:VIV)("Avivagen")是一家专注于开发和商业化牲畜、伴侣动物和人类应用产品的生命科学公司,安全地提高饲料摄入量并支持免疫功能,从而支持总体健康和表现,日前宣布其2023年第二季度未经审计的财务业绩。
Avivagen首席执行官Kym Anthony表示:"特别委员会将继续研究所有潜在的替代方案,包括对公司进行全部或部分的战略出售"。"到目前为止,Avivagen已经收到了许多希望就此类替代方案进行初步讨论的公司的回复"。
2023年4月30日第二季度财务业绩
公司截至2023年4月30日的第二季度未经审计的财务报表以及随附的管理层讨论与分析已经在电子文件分析与检索系统上备案,并可通过其网站查阅。截至2023年4月30日的第二季度的财务信息应与公司未经审计的财务报表以及截至2023年4月30日的第二季度的管理层讨论和分析一起阅读。
公司报告截至2023年4月30日的三个月期间,净收入为77,683美元,综合亏损为(1,244,829)美元。相比之下,截至2022年4月30日的三个月期间的收入为88,438美元,全面亏损为(1,303,677)美元。
在截至2023年4月30日的六个月期间,公司报告的净收入为143,722美元,综合亏损为(2,398,759)美元。相比之下,截至2022年4月30日的六个月期间,收入为359,595美元,综合损失为(2,856,529)美元。
截至2023年4月30日,公司报告的总资产为324,686美元(流动资产为266,140美元),总负债为8,633,272美元,股东赤字为(8,308,586)美元。
关于Avivagen
Avivagen是一家生命科学公司,专注于为牲畜、伴侣动物和人类应用开发和商业化产品,通过安全地支持免疫功能,促进总体健康和表现。它是一家在多伦多证券交易所创业板上市的上市公司,股票代码为VIV,总部设在加拿大渥太华,是加拿大国家研究委员会的合作机构。该网站的内容明确地没有被纳入本新闻稿的参考。
关于OxC-beta技术和OxC-beta畜牧业
Avivagen的OxC-beta技术源于安维根对β-胡萝卜素和其他类胡萝卜素的发现,这些化合物使某些水果和蔬菜具有明亮的色彩。通过对免疫功能的支持,该技术提供了一种非抗生素的手段来促进健康和生长。OxC-β家畜是一种专利产品,被证明是一种有效和经济的替代品,可以替代通常添加到家畜饲料中的抗生素。该产品目前可在美国、墨西哥、菲律宾、中国台湾、新西兰、泰国、澳大利亚和马来西亚销售。OxC-beta已经被喂给了超过4660万头食用动物(家禽、猪和乳牛)、133,820只狗和4000人。
安维根的OxC-beta家畜产品是安全、有效的,并且可以实现全球取消所有饲料中抗生素作为生长促进剂的任务。许多使用OxC-beta牲畜产品的家禽和猪的国际牲畜试验证明,该产品的性能与饲料中的抗生素一样好,有时在某些方面甚至比抗生素更好。